Big Pharma’s R&D spending flatlined in 2022: What it means for the industry

Research and development (R&D) spending by drug manufacturers flatlined in 2022, according to data released by Evaluate Vantage Friday morning.

Among the world’s largest 11 drugmakers, only AstraZeneca and Sanofi showed any “real uptick” in R&D investment, as the urgency to develop treatments for COVID-19 fell by the wayside.